- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
27matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / Amgen | RecruitingVerified 2026-07 | Phase 312,800 estimated | 776 recruiting782 listed / 36 countries | Jun 30, 2028estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07037433 ↗ |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / Amgen | RecruitingVerified 2026-06 | Phase 35,056 estimated | 624 recruiting628 listed / 34 countries | Jun 30, 2028estimated | Jul 2, 2026ClinicalTrials.gov | Open NCT07037459 ↗ |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686 / MARITIME-OSA-1 / Amgen | RecruitingVerified 2026-06 | Phase 3250 estimated | 60 recruiting60 listed / 11 countries | Sep 29, 2027estimated | Jun 12, 2026ClinicalTrials.gov | Open NCT07225686 ↗ |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765 / MARITIME-OSA-2 / Amgen | RecruitingVerified 2026-06 | Phase 3250 estimated | 54 recruiting54 listed / 11 countries | Sep 29, 2027estimated | Jun 12, 2026ClinicalTrials.gov | Open NCT07226765 ↗ |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252 / Amgen | RecruitingVerified 2026-06 | Phase 2180 estimated | 23 recruiting23 listed / 1 countries | Sep 29, 2027estimated | Jun 18, 2026ClinicalTrials.gov | Open NCT07441252 ↗ |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399 / Amgen | RecruitingVerified 2026-07 | Phase 3300 estimated | 44 recruiting44 listed / 2 countries | Jan 3, 2028estimated | Jul 23, 2026ClinicalTrials.gov | Open NCT07575399 ↗ |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NCT07684144 / Amgen | Not yet recruitingVerified 2026-06 | Phase 3950 estimated | 0 recruiting0 listed / 0 countries | Dec 26, 2027estimated | Jul 6, 2026ClinicalTrials.gov | Open NCT07684144 ↗ |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235 / Amgen | Not yet recruitingVerified 2026-06 | Phase 33,200 estimated | 0 recruiting0 listed / 0 countries | Dec 26, 2027estimated | Jul 6, 2026ClinicalTrials.gov | Open NCT07684235 ↗ |
| A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)NCT06660173 / Amgen | Active, not recruitingVerified 2025-11 | Phase 2409 actual | 0 recruiting96 listed / 14 countries | Oct 6, 2025actual | Nov 25, 2025ClinicalTrials.gov | Open NCT06660173 ↗ |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 / MARITIME-1 / Amgen | Active, not recruitingVerified 2025-10 | Phase 33,853 actual | 0 recruiting243 listed / 17 countries | Jan 21, 2027estimated | Oct 20, 2025ClinicalTrials.gov | Open NCT06858839 ↗ |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 / MARITIME-2 / Amgen | Active, not recruitingVerified 2025-12 | Phase 31,105 actual | 0 recruiting187 listed / 13 countries | Jan 21, 2027estimated | Dec 31, 2025ClinicalTrials.gov | Open NCT06858878 ↗ |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseaseNCT06987695 / MARITIME-3-J / Amgen | Active, not recruitingVerified 2025-12 | Phase 3279 actual | 0 recruiting30 listed / 1 countries | Apr 27, 2027estimated | Dec 17, 2025ClinicalTrials.gov | Open NCT06987695 ↗ |
| A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257 / Amgen | Active, not recruitingVerified 2026-06 | Phase 156 actual | 0 recruiting1 listed / 1 countries | Nov 15, 2026estimated | Jun 12, 2026ClinicalTrials.gov | Open NCT07160257 ↗ |
| Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityNCT07229157 / Amgen | Active, not recruitingVerified 2026-01 | Phase 181 actual | 0 recruiting2 listed / 1 countries | Aug 26, 2026estimated | Jan 23, 2026ClinicalTrials.gov | Open NCT07229157 ↗ |
| Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711 / Amgen | Active, not recruitingVerified 2026-07 | Phase 149 actual | 0 recruiting2 listed / 1 countries | Nov 18, 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07523711 ↗ |
| Single and Multiple Ascending Dose Study of AMG 133 in Participants With ObesityNCT04478708 / Amgen | CompletedVerified 2025-11Registry results posted | Phase 1110 actual | 0 recruiting3 listed / 1 countries | Nov 18, 2022actual | Dec 10, 2025ClinicalTrials.gov | Open NCT04478708 ↗ |
| Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian ParticipantsNCT05056246 / Amgen | CompletedVerified 2025-01Registry results posted | Phase 134 actual | 0 recruiting1 listed / 1 countries | Apr 8, 2022actual | Feb 25, 2025ClinicalTrials.gov | Open NCT05056246 ↗ |
| Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusNCT05669599 / Amgen | CompletedVerified 2026-01 | Phase 2592 actual | 0 recruiting78 listed / 12 countries | Oct 8, 2024actual | Jan 20, 2026ClinicalTrials.gov | Open NCT05669599 ↗ |
| A Study to Evaluate AMG 133 in Chinese Participants With Obesity or OverweightNCT06352892 / Amgen | CompletedVerified 2026-01 | Phase 120 actual | 0 recruiting1 listed / 1 countries | Aug 27, 2024actual | Jan 8, 2026ClinicalTrials.gov | Open NCT06352892 ↗ |
| A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or ObesityNCT06976372 / Amgen | CompletedVerified 2025-10 | Phase 1120 actual | 0 recruiting3 listed / 1 countries | Dec 27, 2024actual | Oct 8, 2025ClinicalTrials.gov | Open NCT06976372 ↗ |
| Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsNCT07226778 / Amgen | CompletedVerified 2026-06 | Phase 1348 actual | 0 recruiting4 listed / 1 countries | May 28, 2026actual | Jun 17, 2026ClinicalTrials.gov | Open NCT07226778 ↗ |
| A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityNCT07310563 / Amgen | CompletedVerified 2025-12 | Phase 159 actual | 0 recruiting1 listed / 1 countries | May 9, 2025actual | Dec 30, 2025ClinicalTrials.gov | Open NCT07310563 ↗ |
| A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsNCT07313761 / Amgen | CompletedVerified 2026-07 | Phase 1349 actual | 0 recruiting4 listed / 1 countries | Jun 26, 2026actual | Jul 16, 2026ClinicalTrials.gov | Open NCT07313761 ↗ |
| A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic FunctionNCT07428525 / Amgen | CompletedVerified 2026-03 | Phase 136 actual | 0 recruiting5 listed / 1 countries | Feb 26, 2026actual | Mar 11, 2026ClinicalTrials.gov | Open NCT07428525 ↗ |
| The Effect of AMG 133 on Gastric EmptyingNCT07429032 / Amgen | CompletedVerified 2025-12 | Phase 157 actual | 0 recruiting1 listed / 1 countries | Nov 26, 2025actual | Feb 24, 2026ClinicalTrials.gov | Open NCT07429032 ↗ |
| A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the BodyNCT07429045 / Amgen | CompletedVerified 2025-12 | Phase 144 actual | 0 recruiting5 listed / 1 countries | Nov 21, 2025actual | Feb 24, 2026ClinicalTrials.gov | Open NCT07429045 ↗ |
| A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityNCT07717814 / Amgen | CompletedVerified 2026-07 | Phase 1154 actual | 0 recruiting4 listed / 1 countries | May 22, 2025actual | Jul 21, 2026ClinicalTrials.gov | Open NCT07717814 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →